Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
02. Mai 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
20. April 2022 07:30 ET
|
Otonomy, Inc.
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
15. März 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28. Februar 2022 16:27 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy to Participate in Two Upcoming Investor Conferences
28. Februar 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
25. Februar 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
22. Februar 2022 07:30 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
17. Februar 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
16. Februar 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
25. Januar 2022 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...